1-(2-甲基丁酰)哌啶 | 46034-20-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(2-甲基丁酰)哌啶
• 英文名称: 1-(2-Methylbutyryl)piperidine
• 英文别名: 2-methyl-1-piperidin-1-ylbutan-1-one
• CAS: 46034-20-2
• 化学式: C₁₀H₁₉NO
• 分子量: 169.26
• InChiKey: DLBXFSLJOBEJOJ-UHFFFAOYSA-N

物化性质

• 沸点：
  275.5±9.0 °C(Predicted)
• 密度：
  0.947±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090

文献信息

• DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE
  申请人：Nagashima Shinya

  公开号：US20110294749A1

  公开（公告）日：2011-12-01

  A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

  提供了一种可用于预防或治疗涉及STAT 6的呼吸系统疾病，特别是哮喘、慢性阻塞性肺疾病等的化合物。该化合物为嘧啶衍生物或其盐，其在2位具有可以被指定取代基取代的芳基氨基或芳基乙基氨基基团，在4位具有可以被苄基或类似物取代的氨基基团，并在5位具有可以被取代的氨基甲酰基团。
• SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES
  申请人：Li Yun-Long

  公开号：US20110224189A1

  公开（公告）日：2011-09-15

  The present invention provides compounds of the formula: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了化合物的公式：其对映异构体，对映体混合物，前药，晶体形式，非晶体形式，无定形形式，其溶剂化物，代谢产物以及药学上可接受的盐，其中环A的取代基在以下披露中完全定义。公式化合物是金属蛋白酶抑制剂，例如基质金属蛋白酶和剪切酶，并且在治疗风湿性关节炎，牛皮癣，肿瘤性疾病，过敏和所有需要抑制MMP的疾病中有用。
• Lincomycin Derivatives and Antimicrobial Agents Comprising the Same as Active Ingredient
  申请人：Umemura Eijirou

  公开号：US20090156512A1

  公开（公告）日：2009-06-18

  This invention provides compounds of formula (I) or its pharmacologically acceptable salt or solvate, wherein A represents aryl or a monocyclic or bicyclic heterocyclic group, R 1 represents a halide, nitro, substituted C 1-6 alkyl, optionally substituted amino, C 1-6 alkyloxycarbonyl, optionally substituted aryl, a heterocyclic group, or heterocyclic carbonyl, R 2 represents a hydrogen atom or C 1-6 alkyl, R 3 represents C 1-6 alkyl, all of R 4 , R 5 , and R 6 represent a hydrogen atom, R 7 represents C 1-6 alkyl, m is 1 or 2, and n is 1. The compounds are novel lincomycin derivatives having a potent activity against resistant pneumococci. The compounds can be used as an antimicrobial agent and are useful for preventing or treating bacterial infectious diseases.

  本发明提供了式（I）的化合物或其药理学上可接受的盐或溶剂，其中A代表芳基或单环或双环杂环基，R1代表卤素、硝基、取代的C1-6烷基、可选取代的氨基、C1-6烷氧羰基、可选取代的芳基、杂环基或杂环羰基，R2代表氢原子或C1-6烷基，R3代表C1-6烷基，R4、R5和R6均代表氢原子，R7代表C1-6烷基，m为1或2，n为1。这些化合物是新型的林可霉素衍生物，对耐药性肺炎球菌具有强大的活性。这些化合物可以用作抗微生物剂，并且对于预防或治疗细菌感染性疾病是有用的。
• Acrylamide-based copolymers, terpolymers, and use as hydrate inhibitors
  申请人：Saudi Arabian Oil Company

  公开号：US10189986B2

  公开（公告）日：2019-01-29

  Copolymers having General Formula (I): in which R1, R2, and R3 are chosen from C1 to C30 aliphatic groups, R4 is chosen from divalent C4 to C7 linear aliphatic groups and divalent C4 to C7 linear heteroaliphatic groups, optionally substituted with one or more C1-C6 linear aliphatic groups, C1-C6 branched aliphatic groups, or combination thereof, R5, R6, and R7 are each independently chosen from methyl or hydrogen, x is chosen from 0 to 0.8, y is chosen from 0 to 0.8, when y is 0, x is greater than 0, and when x is 0, y is greater than 0, and z is chosen from 0.1 to 0.9. The summation of x, y, and z equals 1. Methods for inhibiting formation of clathrate hydrates in a fluid capable of forming the clathrate hydrates, including contacting the fluid with at least one copolymer of General Formula (I).

  具有通式 (I) 的共聚物： 其中 R1、R2 和 R3 选自 C1 至 C30 脂肪族基团，R4 选自二价 C4 至 C7 直链脂肪族基团和二价 C4 至 C7 直链杂脂肪族基团，任选被一个或多个 C1-C6 直链脂肪族基团、C1-C6 支链脂肪族基团或其组合取代，R5、R6 和 R7 各自独立地选自甲基或氢，x 选自 0 至 0.8，y 选自 0 至 0.8，当 y 为 0 时，x 大于 0，当 x 为 0 时，y 大于 0，z 选自 0.1 至 0.9。x、y 和 z 的和等于 1。抑制能形成凝块水合物的流体中凝块水合物的形成的方法，包括使流体与至少一种通式(I)的共聚物接触。
• [EN] GEMCITABINE ANTICANCER DERIVATIVE AND ANTICANCER PHARMACEUTICAL USE<br/>[FR] DÉRIVÉ ANTICANCÉREUX DE GEMCITABINE ET UTILISATION PHARMACEUTIQUE CONTRE LE CANCER<br/>[ZH] 吉西他滨抗癌衍生物及抗癌医药用途
  申请人：[en]ASCENTAWITS PHARMACEUTICALS, LTD.;[zh]深圳艾欣达伟医药科技有限公司

  公开号：WO2022258043A1

  公开（公告）日：2022-12-15

  本发明提供式(Ⅲ)的吉西他滨抗癌衍生物及抗癌医药用途，这些化合物有潜力被开发为AKR1C3活化的抗癌药物。